Clinical Trials
228 trialsCOSMIC
ASH Research Collaborative
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Fondazione IRCCS Policlinico San Matteo di Pavia
iPREFER
The Christie NHS Foundation Trust
A Real-world Study in Participants With Smoldering Multiple Myeloma
Janssen-Cilag Ltd.
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
National Institutes of Health Clinical Center (CC)
MED-hATTR
The Cleveland Clinic
A Study of Ninlaro in Real World Clinical Practice in China
Takeda
Biomarkers of AKI in Patients Receiving Daratumumab
Brigham and Women's Hospital
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
Mayo Clinic
NIRVANA
Columbia University
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Multiple Myeloma Prognostic Indices
Assiut University
Financial Difficulty in Patients With Blood Cancer
UNC Lineberger Comprehensive Cancer Center
Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
Asan Medical Center
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Stanford University
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
Odense University Hospital
LOOMIS
Oxford University Hospitals NHS Trust
DILEMMA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
KEEPER
Azienda USL Reggio Emilia - IRCCS
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
Mayo Clinic
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
Mayo Clinic
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Pomalyst PMS
Celgene
LocoMMotion
Janssen-Cilag Ltd.
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
PeriPharm
FKTMM2022
Azienda USL Reggio Emilia - IRCCS
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Duke University
Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma
Alliance for Clinical Trials in Oncology
Immune Profiling in Multiple Myeloma
University of Turin, Italy
Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy
Fondazione EMN Italy Onlus
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
UNC Lineberger Comprehensive Cancer Center
ROOT
Taproot Health
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
University of Turin, Italy
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
University of Turin, Italy
A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
RenJi Hospital
Mobile Health Device Study for Myeloma Patients
Memorial Sloan Kettering Cancer Center
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Screening to Improve Survival in AL Amyloidosis
Tufts Medical Center
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
Wake Forest University Health Sciences
MYLENE
iOMEDICO AG
QoL-MM
Odense University Hospital
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
Bristol-Myers Squibb
OMYFIN
University Hospital, Brest
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
Takeda